Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | BAX | Q07812 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.43 |
| ▸ | PNLIP | P16233 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954851 | 1.00 | MEN1 (0.47) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL7028109 | 0.89 | CA12 (0.47) | MEN1KMT2AMMP2CA9CA14 | |
| SCHEMBL7089012 | 0.89 | CA12 (0.47) | MEN1KMT2AMMP2CA9CA14 | |
| SCHEMBL16057214 | 0.89 | CA12 (0.47) | MEN1KMT2AMMP2CA9CA14 | |
| SCHEMBL5955152 | 0.88 | MMP2 (0.57) | LTA4HMAPK1MMP2MMP8MMP14 | |
| SCHEMBL5955145 | 0.88 | MMP2 (0.57) | LTA4HMAPK1MMP2MMP8MMP14 | |
| SCHEMBL6169593 | 0.85 | CA2 (0.56) | MEN1KMT2AMMP2MMP8MMP14 | |
| SCHEMBL6169592 | 0.85 | CA2 (0.56) | MEN1KMT2AMMP2MMP8MMP14 | |
| SCHEMBL5954543 | 0.85 | SCN9A (0.55) | MAPK1MMP2MMP8MMP14CA9 | |
| SCHEMBL5954546 | 0.85 | SCN9A (0.55) | MAPK1MMP2MMP8MMP14CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LABORATOIRES FOURNIER S.A. (FR) | 2006-02-02 | — | — | US | disclosed |
| EP-1546111-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031160-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LIPC, CYP4F2, SLC5A2 | MEN1 3372/4885KMT2A 1991/4885ESR1 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.